Abatacept: all 220 studies that test it
Page 3 of 3. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/UniversalisWithdrawnNCT01314495Phase 2
- SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.CompletedNCT01295151Phase 4
- Study on the Safety of Abatacept in Relapsing PolychondritisCompletedNCT01272856Phase 1
- Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of AbataceptWithdrawnNCT01221636Phase 1
- Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic PatientsWithdrawnNCT01033500Not applicable
- Pilot Open Label Clinical Trial With Abatacept in Ankylosing SpondylitisStatus unknownNCT00558506Phase 2
- Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes MellitusCompletedNCT00501709Phase 1/2
- Abatacept in ANCA Associated VasculitisTerminatedNCT00482066Phase 2
- LEA29Y (Belatacept) Emory Edmonton ProtocolCompletedNCT00468403Phase 2
- A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving MethotrexateCompletedNCT00345748Phase 2
- Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCompletedNCT00306878Phase 1
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCompletedNCT00287547Phase 2
- Vaccination Study of Abatacept (BMS-188667) for Normal Healthy VolunteersCompletedNCT00279734Phase 1
- A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisCompletedNCT00277225Phase 1
- Comparability DE vs CD-CHO1CompletedNCT00277199Phase 1
- The Study of Abatacept in Combination With EtanerceptCompletedNCT00162279Phase 2
- An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF TherapyCompletedNCT00162201Phase 1
- Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)CompletedNCT00094380Phase 1/2
- Safety of RG2077 in Patients With Multiple SclerosisCompletedNCT00076934Phase 1
- A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple SclerosisTerminatedNCT00035529Phase 2